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Spinal muscular atrophy (SMA) is a pediatric genetic disease, characterized by motor
neuron (MN) death, leading to progressive muscle weakness, respiratory failure, and,
in the most severe cases, to death. Abnormalities at the neuromuscular junction (NMJ)
have been reported in SMA, including neurofilament (NF) accumulation at presynaptic
terminals, immature and smaller than normal endplates, reduced transmitter release, and,
finally, muscle denervation. Here we have studied the role of agrin in SMA17 mice, the
experimental model of SMAII. We observed a 50% reduction in agrin expression levels
in quadriceps of P10 SMA mice compared to age-matched WT controls. To counteract
such condition, we treated SMAmice from birth onwards with therapeutic agrin biological
NT-1654, an active splice variant of agrin retaining synaptogenic properties, which is also
resistant to proteolytic cleavage by neurotrypsin. Mice were analyzed for behavior, muscle
and NMJ histology, and survival. Motor behavior was significantly improved and survival
was extended by treatment of SMA mice with NT-1654. At P10, H/E-stained sections of
the quadriceps, a proximal muscle early involved in SMA, showed that NT-1654 treatment
strongly prevented the size decrease of muscle fibers. Studies of NMJ morphology on
whole-mount diaphragm preparations revealed that NT-1654-treated SMA mice had
more mature NMJs and reduced NF accumulation, compared to vehicle-treated SMA
mice. We conclude that increasing agrin function in SMA has beneficial outcomes
on muscle fibers and NMJs as the agrin biological NT-1654 restores the crosstalk
between muscle and MNs, delaying muscular atrophy, improving motor performance
and extending survival.
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INTRODUCTION
Spinal muscular atrophy (SMA) is a fatal pediatric genetic disease, characterized by selective motor
neuron (MN) degeneration and death, leading to progressive muscle weakness and paralysis,
respiratory failure, and, in the most severe cases, to death. In humans two almost identical SMN
(survival motor neuron) genes are present on chromosome 5q13. SMA is caused by mutations
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in the telomeric gene “survival motor neuron 1” (SMN1),
that consequently cannot encode SMN protein. By contrast
the centromeric SMN2 gene is not affected by the disease:
physiologically SMN2 mostly generates a truncated protein
lacking exon 7 (SMN17), and only a limited amount of
functional full length protein. SMN2 may exist in several copies
and the copy number of SMN2 modulates the disease severity,
depending on the amount of functional protein produced
(Lorson et al., 2010). Based on the age of onset and disease
severity, SMA can be classified into four main clinical types
(I–IV from severe to mild) (Lefebvre et al., 1997). Currently a
new therapy aimed at increasing SMN expression raised great
expectations (Finkel et al., 2017), even though additional drugs
are needed to counteract muscular atrophy: SMN is needed in
both neurons and muscles (indeed its requirement is highest
when the neuromuscular system is correctly established during
development); moreover the efficacy of SMN-based treatments
can be poor if the neuromuscular system is compromised, since
delayed symptoms can later affect treated patients (Bowerman
et al., 2017).
SMN, together with Gemins 2 to 7, is involved in the
assembly of small nuclear ribonucleoprotein (snRNP) particles,
and its deficiency can disrupt splicing of specific targets
(Wan et al., 2005). Moreover, it has been suggested that
SMN lack can result in defects in MN β-actin mRNA axonal
transport, neurotransmitter release, neurofilament dynamics and
accumulation at the synapse, and neuromuscular junction (NMJ)
maturation (Pagliardini et al., 2000; Fan and Simard, 2002;
Jablonka et al., 2004; Kariya et al., 2008; Kong et al., 2009; Torres-
Benito et al., 2011). Indeed, SMA17 mice, the experimental
model of SMAII, recapitulate these defects, showing reduced
synaptic vesicle density and concomitant synaptic transmission
defects (Dale et al., 2011). Post-natal development of the NMJs
is arrested in SMA, which impairs the maturation of endplate
acetylcholine receptors (AChRs), determining a delay in the
developmental switch from embryonic γ-subunit containing
AChRs to the mature ǫ-subunit containing AChRs (Wyatt
and Keirstead, 2010). Therefore, SMA murine models show
abnormalities of NMJs, including neurofilament accumulation at
presynaptic terminals, smaller and immature endplates, reduced
transmitter release, and denervation (Ling et al., 2010).
The NMJ formation is physiologically promoted by the
neurotrypsin/agrin system. Agrin, a large heparan sulfate
proteoglycan, is a synaptic organizer responsible for NMJ
development, i.e., insertion of a nerve terminal, clustering of
AChRs and maturation of NMJs (Bolliger et al., 2010): agrin
signals via the surface receptors Lrp4 and MuSK, and other
signaling molecules (such as Dok-7 and rapsyn) to guarantee the
efficiency and functionality of the neuromuscular transmission
(Glass and Yancopoulos, 1997; Zong et al., 2012). Agrin is
cleaved by neurotrypsin, a member of the serine protease family
Abbreviations: AChRs, acetylcholine receptors; BTX, α-bungarotoxin;
COX, Cytochrome c Oxidase; MN, motor neuron; NF, neurofilament; NMJ,
neuromuscular junction; PBS, phosphate buffer solution; SEM, standard error of
mean; SMA, spinal muscular atrophy; SMN, survival motor neuron; snRNP, small
nuclear ribonucleoprotein.
S1A, at two homologous, highly conserved sites, resulting in
the release of the C-terminal domain (agrin-22) containing the
NMJ-organizing and protecting function (Reif et al., 2007). Such
cleavage inactivates the AChR clustering activity of agrin.
Here we have studied the role of agrin in preventing muscular
atrophy in SMA as we hypothesized that stabilization of NMJs
would improve the crosstalk between muscle fibers and MNs
and thus delay disease progression, muscle atrophy and motor
impairment. We therefore daily administered to SMA pups a
C-terminal fragment of mouse agrin, termed NT-1654, which
is neurotrypsin-resistant, highly soluble and retains the AChR-
clustering activity. We provide evidence that this treatment is
effective at the neuromuscular level, delays disease progression
and significantly improves motor performance.
MATERIALS AND METHODS
Animal Care and Genotyping
All procedures involving animals were performed in accordance
with national (DL n. 116, G.U., Supp. 40, February 18,
1992; permit number 17/2010-B, June 30, 2010) and European
Community Council guidelines (Council Directive 86/609/EEC).
Additionally, an ad hoc Ethical Committee of the University of
Turin specifically approved this study. Particular care was taken
to minimize the number of animals, their discomfort and pain.
The original breeding pairs of SMA mice were purchased
from Jackson Laboratory (stock number 005025; Jackson Lab,
Maine, USA). Mice had free access to food and water. The
colony was maintained by interbreeding carrier mice, and
the offspring were genotyped by PCR assays on tail DNA
according to the protocols provided by Jackson Laboratory:
briefly, animals were genotyped for the presence of the two
human transgenes (SMN2 and SMN17) and the three possible
genotype variants of the mouse Smn locus (Smn+/+, Smn+/–
and Smn–/–). Sequences of primers and probes (5
′
-3
′
) used for
WT murine Smn gene are TTTTCTCCCTCTTCAGAGTGAT
(forward), CTGTTTCAAGGGAGTTGTGGC (reverse).
Sequences of primers and probes (5
′
-3
′
) used for mutant murine
Smn gene are TTTTCTCCCTCTTCAGAGTGAT (forward),
GGTAACGCCAGGGTTTTCC (reverse).
Data were obtained from tissues harvested from SMA
(Smn−/−) and WT (Smn+/+) mice, killed at postnatal day 10
(P10), considering P0 as the day of birth. Just for western blot
analysis additional animals were sacrificed at P5.
In order to reduce the number of used animals,
data concerning quadriceps histological examination
(hematoxylin/eosin staining and Cytochrome c Oxidase
assay) on untreated pups were the same as in another paper
published (Valsecchi et al., 2015).
Agrin Western Blotting
Agrin expression in SMA and WT mice was measured at P5 (3
WT and 4 SMA) and at P10 (4 WT and 3 SMA). Animals were
killed by cervical dislocation and their quadriceps were rapidly
dissected on ice. Muscles were homogenized in liquid nitrogen
and collected in ice-cold lysis buffer (20mM Hepes pH 7.5, 1%
Triton, 150mM NaCl, 10mM NaF, 1mM Na3VO4, 0.5µg/ml
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apronitin, 1µg/ml leupeptin, 1µg/ml pepstatin). The samples
were then cleared by centrifugation and the supernatant was
used for Western blot analysis after protein determination by the
Bio-Rad protein assay (Biorad, Milan, Italy). Samples with equal
protein concentration were resolved by SDS-PAGE on 4–12%
NUPAGE gels usingMES running buffer (Life Technologies) and
subsequently blotted to nitrocellulose membrane (Ge Healthcare,
Milan, Italy). To detect the proteins of interest, specific antibodies
were used: anti-agrin (mouse monoclonal, low affinity anti-C22
antibody, 1.5µg/ml), provided by Dr. Hettwer (Stephan et al.,
2008), and anti-GAPDH (mouse monoclonal, 1:1,000, Millipore,
Temecula, CA, USA). Immunoreaction was revealed using anti-
mouse IgG conjugated to peroxidase, 1:4,000 (Ge Healthcare)
by the ECL reagent (Ge Healthcare). The optical density of the
bands was determined by Chemi Doc Imaging System (Biorad)
and normalized to the optical density of GAPDH.
Agrin Administration
The agrin biological NT-1654 was designed (US20120208765
A1 patent number), synthesized and supplied by Neurotune
AG (Schlieren, Switzerland). It consists of a 44 kDa protein
containing the C-terminal part of the 220 kDa full-length agrin. It
corresponds to an active splice variant of agrin that is secreted by
theMNs and includes the “synapse-inducing” activity. To protect
it from the cleavage by neurotrypsin, it is mutated at the cleavage
site.
NT-1654 (10 mg/kg) was administered subcutaneously daily
in SMA mice, starting from P0. This agrin formulation is highly
soluble and the administration route is effective to reach all
neuromuscular target site. Moreover, this concentration has been
demonstrated to be safe and therapeutic when employed in a
sarcopenia murine-model (Hettwer et al., 2014). Sham-injected
pups received sterile phosphate buffer solution (PBS; pH 7.3).
For histological examination, the animals were sacrificed at
P10 (NT-1654 SMA n = 12, PBS SMA n = 15). In another set of
experiments, additional mice (PBS SMA n= 20, NT-1654 SMA n
= 19) were used for survival analysis.
Behavioral Tests
Motor behavior and wellness of the animals were assessed every
second day, starting from P2 (NT-1654 SMA n = 27, PBS SMA
n = 15). Before starting the behavioral tests, the animals were
weighed. According to El-Khodor et al. (2008), a battery of
behavioral tests have been selected: (i) Righting reflex. Pups were
placed on their backs on a flat surface. The time employed to
right themselves was recorded (cut off 30 s). (ii) Tail suspension
test (self-clasping). Pups were suspended by the tail for 15 s
and their hindlimb posture was scored: 4, hindlimbs spread
open; 3, hindlimbs not completely spread; 2, hindlimbs often
close together; 1, hindlimbs always close together; 0, hindlimbs
always close together with clasping. (iii) Hindlimb suspension
test (tube test). The test required two consecutive trials; in
each trial, the mouse was placed head down, hanging by its
hindlimbs in a plastic 50ml tube with a cotton ball cushion at
the bottom to protect the animal in case of fall. We considered
two parameters: the latency to fall (time) from the edge of the
tube and the hindlimb score: 4, normal hindlimb separation with
tail raised; 3, apparent weakness and hindlimbs close together
without touching each other; 2, close hindlimbs, often touching;
1, hindlimbs always clasping with the tail raised; 0, constant
clasping of the hindlimbs with the tail lowered. (iv) Negative
geotaxis. P4 and older mice underwent this test, useful to evaluate
motor coordination and vestibular sensitivity. The animals were
placed on an inclined grid (at approximately 35◦ inclination) with
the mouse head facing down. We measured the time needed for
mice to orient themselves (cut off 60 s) and we assigned 60 s also
to mice unable to complete the test.
Spinal Cord Histological Examination
P10 mice (NT-1654 SMA n = 11, PBS SMA n = 9) were deeply
anesthetized by gaseous anesthesia (3% isoflurane vaporized in
O2/N2O 50:50) and perfused transcardially with 4% buffered
paraformaldehyde (PFA, pH 7.4). The spinal cord was removed,
cut between L1 and L5 vertebral segments, and postfixed in
4% PFA for 2 h at 4◦C. Samples were immersed overnight in
a solution containing 30% sucrose in phosphate buffer (PB)
0.1M at 4◦C for cryoprotection, embedded in cryostat medium
(Killik; Bio-Optica, Milan, Italy) and cut on the cryostat (HM
550; Microm) in serial transverse 20µm thick sections, mounted
directly onto 5% gelatin-coated slides and stained with cresyl
violet (Sigma Aldrich, St. Louis, MO, USA) for Nissl staining.
Spinal MNs (NT-1654 SMA n = 5, PBS SMA n = 5)
were counted on serial sections (1 every 600µm), using a
stereological technique, the Optical Fractionator, a computer-
assisted microscope and the StereoInvestigator software
(MicroBrightField, Williston, VT, USA). Cells were counted
on the computer screen using an Optronics MicroFire digital
camera mounted on a Nikon Eclipse E600 microscope. Only
neurons in the lumbar tract with an area ≥80 µm2 (classified as
alpha MNs) and located in a congruent position were counted.
Quadriceps Histological Examination
Quadriceps muscles were collected from the same animals and
processed, as previously described (Valsecchi et al., 2015). The
muscles underwent different histological approaches.
Hematoxylin/Eosin Staining
We evaluated mean fiber area, quadriceps cross-sectional area,
mean muscular fiber number of quadriceps muscles and
minimal Feret’s diameter (NT-1654 SMA n = 6, PBS SMA
n = 5). Muscles were cut on the cryostat in transverse 20
µm-thick sections, mounted onto 5% gelatin-coated slides,
stained with hematoxylin/eosin, dehydrated in graded ethanol
baths (95–100%) and cleared in xylene. Reconstructions and
analysis of the sections have been performed by Neurolucida
software and the associated data analysis software NeuroExplorer
(MicroBrightField).
Cytochrome c Oxidase (COX) Assay
This assay is performed to evaluate fiber type composition: to
this aim, some muscles (NT-1654 SMA n = 4, PBS SMA n = 3)
were cut on the cryostat in transverse 50 µm-thick sections
free-floating in PBS and processed for the COX histochemistry.
The reaction solution was composed of 10ml PBS 0.1M, 0.4 g
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sucrose, 10mg DAB and 5mg cytochrome C (Sigma Aldrich),
and warmed at 37◦C before incubation. Incubation with reaction
solution required 2–3 h at 37◦C on a tilting plate. The dark
COX-stained sections were classified as oxidative fibers (type I),
whereas light ones as glycolytic fibers (type II).
Immunofluorescence
Other sections (NT-1654 SMA n = 5, PBS SMA n = 8),
longitudinally cut (20 µm-thickness) and mounted onto 5%
gelatin-coated slides, were immunoreacted to evaluate NMJ
denervation. Briefly, the permeabilization was performed with
in PBS-TRITON 0.3% at RT on a tilting plate for 20′; then
the sections were incubated with Alexafluor 555-conjugated α-
bungarotoxin (BTX; 1:500; Invitrogen, Milan, Italy) at RT for
30′. To block unspecific binding of the antibody, the sections
were incubated for 30min at room temperature with 0.3%
Triton X-100 and 10% normal donkey serum (Sigma-Aldrich)
in PBS 1X (pH 7.4); after this, the sections were incubated
with the monoclonal antibody anti-neurofilament 165 kDa 2H3
clone (mouse; 1:500; Hybridoma bank, Iowa, USA) in the same
solution at 4◦C overnight, and then with secondary antibody
Alexa488 anti-mouse (1:200; Jackson Immunoresearch; West
Grove, PA, USA) for 1h at RT, followed by 4′, 6 Diamino-2
phenyindole Dilactate (DAPI; Sigma Aldrich) in PBS 1:50 for 3′.
Samples were washed and coverslips were mounted with a drop
of PB 0.1M with glycerol.
A Nikon Eclipse 90i epifluorescence microscope and a Nikon
DS-5Mc digital camera were used to observe and photograph
the sections. For checking double staining and making 3D
reconstructions, some slides were examined with a Leica TCS SP5
confocal laser scanning microscope.
Diaphragm Histological Examination
A separate group of P10 animals (NT-1654 SMA n = 3, PBS
SMA n = 4) was killed by decapitation to collect unfixed
diaphragms for whole mount staining procedure. Diaphragms
were incubated with α-bungarotoxin (BTX) Alexafluor 555-
conjugated (Invitrogen) 1:500 in PBS 1X for 30′ at room
temperature (RT), washed with PBS and fixed with 2% buffered
PFA for 10′ at RT. Samples were then permeabilized with 1%
Triton X-100 in PBS overnight (ON) at 4◦C. After incubation
with a neutralizing solution for 15′ at RT to block the free
PFA (100mM glycine in PBS), diaphragms were incubated with
0.2% Triton X-100 and 5% normal donkey serum (Sigma-
Aldrich) in PBS, to block non-specific binding sites for at least
30min at 4◦C. Samples were then incubated with monoclonal
anti-neurofilament 165 kDa 2H3 clone antibody (mouse; 1:500,
Hybridoma bank) in blocking solution, overnight at 4◦C.
After washing for 1 h at 4◦C, diaphragms were incubated
with secondary Alexa488 anti-mouse antibody (1:200; Jackson
Immunoresearch) for 2 h at 4◦C. After washing at 4◦C, samples
were incubated in DAPI (Sigma Aldrich) in PBS 1:50 for 3′.
Diaphragms were washed with PBS 1X, and finally coverslipped
with a drop of PB 0.1M with glycerol.
To study NMJ structure and maturation, we analyzed the
slices with a Leica TCS SP5 confocal laser scanning microscope
(NT-1654 SMA n = 3, PBS SMA n = 4); moreover, for assessing
neurofilament accumulation (NT-1654 SMA n = 2, PBS SMA n
= 3), we used the isosurface module of Imaris software (Bitplane,
Zurich, CH).
NT-1654 Administration in P10 WT Animals
To evaluate the impact of NT-1654 administration on
development in physiological conditions, we also injected
the compound into WT pups (NT-1654 WT), from P2 to P10.
Control WT mice received PBS (PBS WT).
The animals (NT-1654 WT n = 32, PBS WT n = 20)
underwent the above-mentioned behavioral tests. Then, after
the sacrifice at P10, we dissected quadriceps and diaphragm
muscles. The quadriceps were processed for the histological
examination, as described above (NT-1654 WT mice n = 8,
PBS WT n = 6): with Neurolucida software we evaluated mean
fiber area, quadriceps cross-sectional area and minimal Feret’s
diameter. We also analyzed the diaphragm NMJs to study their
structure and maturation, as previously reported (NT-1654 WT
n= 5, PBS WT n= 6).
Statistics
Data are shown as mean ± standard error of mean (SEM). For
the histological and molecular analysis, statistically significant
differences among means were determined by unpaired T-test.
For the body weight, we used two-way ANOVA repeated
measures, followed by post hoc Bonferroni; moreover, according
to El-Khodor et al. (2008), data were also represented as a
Kaplan–Meier plot, defined as the time from one initiating event
(i.e., the birth, P0) to a terminating event: the latter one is
considered “the postnatal day when (1) the animal lagged in body
weight by two standard deviations from the established normal
average body weight gain of the WT controls; and (2) the body
weight remained two standard deviations below the average on
each subsequent days” until the last observation (P10).
For the behavioral tests expressed as score or with data
not normally distributed (i.e., righting reflex, tail suspension
test, hindlimb suspension test-score, negative geotaxis), we
applied contingency table analysis (Fisher exact test), whereas
for the hindlimb suspension test-time (characterized by Gaussian
distribution) we used one-way ANOVA repeated measures,
Finally, for evaluating the animal lifespan, we employed
Kaplan–Meier survival curve that was generated with SPSS v.19
(IBM, Milan, Italy).
Differences were considered to be significant when P < 0.05.
Statistical analysis was performed using GraphPad Prism 6.0
software (GraphPad Software, San Diego, CA) and SPSS v.19
(IBM). Experimenters were always blinded for the genotype and
the treatment of the mice.
RESULTS
Analysis of Muscular/NMJ Morphology and
Agrin Expression in P10 WT and SMA Mice
NMJ and muscular fiber morphology are dramatically altered
in SMA (Boido and Vercelli, 2016). We previously reported
significant differences between SMA and WT pups in terms of
mean fiber area and fiber type composition of quadriceps, an
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early affectedmuscle (Valsecchi et al., 2015). Nowwe have further
highlighted such differences by measuring the minimal Feret’s
diameter, that is the most widely recommended parameter to
determine the muscle fiber size (Dubache-Powell, 2008): after
hematoxylin/eosin staining, WT and SMA fibers were analyzed
by Neurolucida software, and respectively measured 11.61 ±
0.10µm and 10.51 ± 0.10µm (unpaired T-Test, P < 0.001;
Figure 1A).
Moreover also NMJs are strongly affected in SMA, showing
reduced endplate area and increased number of multi-
innervated and denervated NMJs (Valsecchi et al., 2015). SMA
endplates are also characterized by abnormal neurofilament (NF)
accumulation, that we have now quantified, by using Imaris
software: we detected a significant increase of NF in the SMA
mice [6.24± 0.42 (expressed as “gray levels”, GL, as suggested by
the software supplier)] compared to WT (4.22± 0.27) (unpaired
T-test: P < 0.001; Figure 1B).
To evaluate the contribution of agrin in determining the
described alterations, we quantified its expression level in the
quadriceps of SMA mice at P5 and P10 by WB analysis. In
particular, we measured the intensity of the full length protein
(FL-agrin) that appeared approximately at 220 kDa: at P5
we observed a slight decrease of FL-agrin expression in SMA
quadriceps compared to age-matched WT mice (Figures 1C,E;
not significant), whereas at P10 a 50% reduction was evident in
quadriceps of SMA mice in comparison with controls (P < 0.05;
Figures 1D,G).
We also measured the intensity of the proteolytic fragment of
agrin of 110 kDa in both SMA and WT mice at P5 and P10. The
trend was similar to the FL-agrin with a 50% reduction of the
proteolytic fragment in quadriceps of P10 (but not P5) SMN17
mice, compared to age matched WT, indicating that the decrease
in FL agrin was not due to increased cleavage of the protein
(Figures 1C,D,F,H).
Effects of Treatment on General Conditions
and Survival
To test whether the lowering of agrin in SMA may result in
functional changes, we decided to administer NT-1654 to SMA
pups with the hope to stabilize the NMJ and to improve the
crosstalk between muscle fibers and MNs.
FIGURE 1 | Analysis of muscular/NMJ morphology and agrin expression levels in the quadriceps of SMA mice. (A) Minimal Feret’s diameter measured in P10 WT and
SMA quadriceps. (B) Accumulation of neurofilament quantified by Imaris software and expressed as gray level. (C,D) Representative Western blots displaying full
length (FL) agrin protein and the proteolytic fragment of 110 kDa in quadriceps of WT and SMA mice at P5 (C) and at P10 (D). Graphs below each image report the
quantification of FL-agrin/GAPDH protein levels at P5 (E) and P10 (G), and the 110 kDa agrin fragment at P5 (F) and P10 (H). Unpaired T-test, *P < 0.05,
***P < 0.001.
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Compared to the body weight of WT pups that constantly
increased from P0 to P10, the SMA weight, after an initial
moderate increase, at P8 reached a plateau and then started to
decrease until death (data not shown). Administration of NT-
1654 resulted in a slight weight increase in SMAmice (at P10 PBS
SMA 3.78± 0.12 g vs. NT-1654 SMA 4.21± 0.19 g) (Figure 2A).
However as suggested by El-Khodor et al. (2008), this type of
representation (i.e., mean body weight for each group) does
not provide the proper onset of SMA worsening as well as
the proportion of the mice showing symptoms. Therefore, we
converted the previous graph in a Kaplan–Meier plot: in this way
we could observe that PBS SMA mice show an anticipated body
weight reduction compared to NT-1654 SMA mice (Kaplan-
Meier curve, Log-rank Mantel Cox test, P < 0.05), although both
groups were clearly worse than PBS WT (considered the control
mice; Figure 2B).
Additionally, in a separate set of experiments, we analyzed the
NT-1654 efficacy in extending SMA lifespan. NT-1654 SMAmice
showed an evident shift to the right in the survival (Kaplan-Meier
curve, Log-rank statistical test, P< 0.05; Figure 2C); additionally,
the mean day of death was 14.85 ± 0.39 for PBS SMA and 16.21
± 0.33 for NT-1654 SMA (unpaired T-test, P < 0.01).
Behavioral Tests
Starting from P2 until death, the motor performance of treated
and untreated SMA mice was evaluated with a battery of
behavioral tests (Figure 3). In the righting reflex test, NT-1654
administration resulted in a significant improvement in SMA
mice compared to SMA PBS, starting from P8 (Fisher exact test:
at P8, P < 0.05; at P10, P < 0.05). In the tail suspension test,
starting from P4, SMA mice treated with NT-1654 showed a
significant improvement compared to PBS-treated mice (Fisher
exact test: at P4, P < 0.001; at P8, P < 0.001; at P10, P
< 0.05). In the hindlimb suspension test, we considered two
parameters, the score and the time. The scores registered were
not significantly different between treated and untreated mice
(analyzed by Fisher exact test); however, as concerns the latency
to fall (time), at P8 NT-1654 SMAmice showed higher resistance
compared to controls (One-way ANOVA repeated measures: P<
0.05). Finally, we also assessed motor coordination and vestibular
sensitivity by measuring negative geotaxis in P4 to P10 mice.
SMA animals (both treated and untreated) showed difficulties in
completing the test for the entire observation period. However,
even though lacking statistical significance, the performance of
NT-1654 SMA showed better results (49.68 ± 3.85 s) than PBS
SMA mice (58.00± 2.00 s).
Muscle Fiber Analysis
After hematoxylin/eosin staining (Figures 4A,B), we analyzed
the morphology of the muscle samples by Neurolucida software.
We evaluated themean fiber area, the overall muscle (quadriceps)
cross-sectional area, the minimal Feret’s diameter and the mean
number of muscle fibers in treated and untreated SMA pups:
we observed statistically significant differences in the mean fiber
area and in the minimal Feret’s diameter (NT-1654 SMA vs. PBS
SMA; unpaired T-test, P < 0.001). The other parameters, though
showing a positive trend to increase in treated mice, did not
reach statistically significant differences (data are summarized in
Table 1). These results suggest that the treatment prevents the
decrease in size of muscle fibers, without affecting their number.
We also employed COX reaction to classify the fiber types and
to evaluate mitochondrial activity (Figures 4C,D). Treatment
partially affected the fiber type distribution in SMA mice
(differences not statistically significant): type I fibers were
81.86% ± 1.95 in NT-1654 SMA and 88.33% ± 0.33 in PBS
SMA (consequently type II fibers were 18.14% ± 1.95 and
11.67% ± 0.33 respectively; see Table 1). Therefore, NT-1654
administration seems to bring back the fiber type distribution
close to WT mice [type I and type II respectively 82%± 1.82 and
18%± 1.82, as reported in Wyatt and Keirstead (2010)].
Finally, we quantified the percentage of denervated
endplates, studying the quadriceps NMJs immunoreacted
by α-bungarotoxin and neurofilament. NT-1654 administration
in SMA mice decreased the percentage of denervated endplates
(4.33%± 1.36) compared to untreated pups (5.54%± 1.94).
Neuromuscular Junction Analysis
We performed a detailed morphological analysis of NMJs in the
diaphragm. Even though this muscle is less severely affected than
others in SMA, it allows to analyze all its NMJs in a whole-
mount preparation. First of all, we classified the NMJs as mature
(i.e., showing perforations) and immature (no perforations)
(Figures 5A–C) (Bolliger et al., 2010). According to the previous
observations on the quadriceps, the NT-1654 administration
seems partially effective on the SMA diaphragm NMJs: the
treatment increased the percentage of mature NMJs in NT-1654
SMA (74%) compared to PBS SMA (68%), although without
reaching a statistically significant difference (Figure 5C).
FIGURE 2 | NT-1654 improves overall state of wellbeing. (A) Body weight evaluation during time (PBS WT n = 20, NT-1654 SMA n = 27, PBS SMA n = 15). (B)
Event time plot for body weight deviation of PBS SMA, NT-1654 SMA and PBS WT (Kaplan–Meier curve, Log-rank Mantel Cox test, P < 0.05). (C) Kaplan–Meier
survival curve shows that NT-1654 can significantly extends SMA lifespan (PBS SMA n = 20, NT-1654 SMA n = 19; Log-rank statistical test, P < 0.05).
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FIGURE 3 | Behavioral tests. Righting reflex, tail suspension test, hindlimb
suspension test (score and time) and negative geotaxis have been used to
evaluate the motor performance of treated and untreated SMA mice (NT-1654
SMA n = 27, PBS SMA n = 15); Fisher exact test *P < 0.05, ***P < 0.001;
One-way ANOVA repeated measures, #P < 0.05.
Finally, by using Imaris software, we evaluated the NF
accumulation in the NMJs (Figures 5D–F), since it is a SMA
hallmark representing an engulfment at the NMJ level. We
detected a significant reduction of NF in the treated SMA mice
(NT-1654 SMA 4.93 ± 0.51 vs. PBS SMA 6.24 ± 0.42; unpaired
T-test, P < 0.05).
Spinal Motor Neurons Stereological Counts
We performed stereological counts in order to evaluate whether
NT-1654 could also influence MN survival. By StereoInvestigator
software, we counted L1-L5 lumbar MNs: only a slight tendency
to higher MN numbers was evident in treated SMA mice vs.
untreated ones (NT-1654 SMA 8,412.13 ± 964.21 vs. PBS SMA
7,351.84 ± 1,169.34), without reaching a statistically significant
difference.
NT-1654 Administration to WT Animals
To better understand if the observed histological/behavioral
improvements in SMA animals were actually related to the
therapeutic effect of NT-1654, rather than to a general effect on
NMJ/muscle development, we administered the compound to a
group ofWT pups.We evaluated the body weight, the quadriceps
morphology (mean fiber area, overall muscle cross-sectional area,
minimal Feret’s diameter, mean number of muscle fibers), the
diaphragm NMJ maturation, and the behavioral performance.
Although the body weight was not considerably affected by the
treatment (NT-1654WT n= 32, PBSWT n= 20; Figure 6A), we
observed a significant increase in themuscle fiber size (mean fiber
area, quadriceps cross-sectional area, minimal Feret’s diameter;
NT-1654 WT mice n = 8, PBS WT n = 6), as shown in
Figures 6B–F. On the contrary, neither NMJ maturation (NT-
1654 WT n = 5, PBS WT n = 6) nor motor performance (NT-
1654 WT n = 32, PBS WT n = 20) were affected by NT-1654
administration (only in the tail suspension test the treatment
seemed to minimally accelerate the spreading of the hindlimbs
at P2; data not shown). No adverse effects have been observed in
WT mice after NT-1654 administration.
DISCUSSION
Here we evaluated the role of agrin/neurotrypsin system in a
murine model of SMA: we observed that interference with this
system via injection of the neurotrypsin-resistant agrin fragment
NT-1645 exerted beneficial effects on muscle trophism and NMJ
maturation, restoring the crosstalk between muscles and MNs
and improving motor performance and extending survival.
SMA And NMJ Alterations
SMA is characterized by MN degeneration, due to deletion or
mutation of the telomeric SMN1 gene and to the insufficient
efficiency of SMN2 gene: this determines in the affected patients
muscular atrophy, paralysis and reduced lifespan, according to
the disease severity (Lorson et al., 2010). The SMA pathogenesis
has been extensively investigated, but a number of disease
mechanisms are still not fully understood. The SMN complex,
composed of the SMN protein and 7 additional proteins
(Gemin2-8), plays a pivotal role in the assembly and biogenesis
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FIGURE 4 | Analysis of quadriceps muscles. (A,B) The morphology of the muscles is highlighted by hematoxylin/eosin staining: NT-1654 administration increases the
fiber size of SMA mice (NT-1654 SMA n = 6, PBS SMA n = 5). (C,D) COX reaction was used to classify the fiber types: NT-1654 treatment changed the fiber type
distribution in SMA mice (NT-1654 SMA n = 4, PBS SMA n = 3). Scale bar = 25µm in (A,B), 35µm in (C,D).
TABLE 1 | Morphological analysis of quadriceps fibers.
NT-1654 SMA PBS SMA
Mean fiber area 141.18 ± 2.39# 127.39 ± 2.09
Quadriceps area 3,083,940 ± 230,939 2,595,276 ± 61,307
Min Feret’s diam 11.20 ± 0.10# 10.51 ± 0.10
Fiber number 7,602.53 ± 860.16 7,206.65 ± 1,361.71
% Fiber I 81.86 ± 1.95 88.33 ± 0.33
% Fiber II 18.14 ± 1.95 11.67 ± 0.33
The mean fiber area (µm2 ), the overall muscle cross-sectional area (µm2 ), the minimal
Feret’s diameter (µm), the mean number of muscle fibers and the fiber distribution were
analyzed in treated and untreated SMA. Data are reported as mean ± SEM, statistical
analysis was performed with unpaired T-test (NT-1654 SMA n = 6, PBS SMA n = 5).
Mean fiber area and minimal Feret’s diameter: NT-1654 SMA vs. PBS SMA #P < 0.001.
of snRNPs, and in pre-mRNA splicing. SMN is reported
to be also involved in the transport of axonal mRNAs in
MNs, for example functioning as a molecular chaperone for
β-actin messenger RNA localization in axons (Kolb et al.,
2007; Tsai, 2012). Additionally, SMN is implicated in the
stabilization and maturation of the NMJ: indeed, human SMA
patients and experimental mouse models display consistent
electrophysiological changes accompanied by a disruption of
NMJ connectivity and denervation of skeletal muscles (Murray
et al., 2010).
NMJs are specialized synapses in the peripheral nervous
system, which allow the transmission between the motor nerve
terminal and skeletal muscle fibers. As reviewed by Witzemann
(2006), in physiological conditions, starting from embryonic
days (E) 12–14 in mouse, AChRs are prepatterned at sites
where the outgrowing MNs will form synaptic contacts; the
mature endplates become stabilized at E17. During postnatal
development, further structural changes occur and AChR
aggregates are rearranged, acquiring the characteristically shaped
“pretzel like” pattern.
Some molecular mechanisms are probably altered at the
NJMs of SMA patients and consequently one of the earliest
defects of SMA is found distal to the α-MNs, at the endplate
level. As reviewed by Goulet et al. (2013), many studies suggest
that in SMA the distribution of NMJs establishes at first as in
controls, then several perturbations and the failure of synapse
maturation lead to their loss, muscular denervation and, finally,
symptom onset. Indeed, some authors have proposed a delayed
development of SMA NMJs: AChR plaques appear immature in
morphology, motor nerve terminal fails to produce the normal
number and distribution of synaptic vesicles, many fibers retain
polyneuronal innervation far longer than expected. Since these
characteristics are typical of younger stages of neuromuscular
development, the hypothesis is that SMA pathology delays the
correct development (Kong et al., 2009; Lee et al., 2011). One
possible reason explaining such abnormalities could be related to
the role of the SMN protein in the generation of the pre-mRNA
splicing machinery and mRNA biogenesis: indeed the lack of
SMN may affect the production of incorrectly spliced transcripts
involved in NMJ establishment/maintenance.
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FIGURE 5 | Analysis of diaphragm NMJs. (A–C) Evaluation of NMJ maturation by BTX-immunostaining: NT-1654 injection partially stimulates NMJ maturation in
treated SMA (B) compared to PBS SMA (A), as quantified in (C). Mature endplates are indicated by arrowheads. (D–F) Double immunostaining against BTX (red) and
NF (green) is employed for analyzing NF accumulation into the plaques: NT-1654 SMA (E) display a significantly lower number of engulfed NMJs (arrows) compared to
PBS SMA (D), as also quantified in (F). Unpaired T-test, *P < 0.05. Scale bar = 25 µm in (A,B,D,E).
The muscle-nerve crosstalk is fundamental in regulating the
formation of synapses, in association with an intricate interplay
of many signaling molecules, including agrin, Lrp4, MuSK, Dok7
and rapsyn (Witzemann, 2006; Bolliger et al., 2010; Punga and
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FIGURE 6 | NT-1654 effects on P10 WT pups. (A) Body weight evaluation during time (PBS WT n = 20, NT-1654 WT n = 32). (B–F) Evaluation of mean fiber area
(B), quadriceps cross-sectional area (C), and minimal Feret’s diameter (D) in hematoxylin/eosin stained WT quadriceps (E,F) (NT-1654 WT mice n = 8, PBS WT
n = 6; unpaired T-test, *P < 0.05, ***P < 0.001). Scale bar = 25µm in (E,F).
Ruegg, 2012). Neurotrypsin is a member of the serine protease
family S1A, predominantly found in the brain, the kidney, and
the lung. Recent studies identified the proteoglycan agrin as the
so far unique target of neurotrypsin. Agrin is a large heparan
sulfate proteoglycan, expressed in neuronal as well as non-
neuronal tissues. Neurotrypsin cleaves agrin at two sites (α and β)
(Reif et al., 2008): the region of agrin corresponding to the 90-kDa
fragment was shown to interact specifically with α-dystroglycan,
integrins, and heparin that are expressed by neurons or astroglia
enclosing the synapse; similarly, the 22-kDa agrin fragment was
shown to be required to induce postsynaptic differentiation via
its binding to Lrp4 (Stephan et al., 2008; Zong et al., 2012).
Therefore, agrin is the synaptic organizer responsible for NMJ
development, including the insertion of a nerve terminal, the
clustering of AChRs and the maturation of NMJs (Bolliger et al.,
2010).
SMA pups display at the NMJ reduced synaptic vesicle
density, altered transmission, NF accumulation, immature and
denervated endplates. The loss of innervation would result from
defects in synapse maintenance, and also NF accumulation
would be independent from NMJ vulnerability to denervation
(Ling et al., 2010). Such neuropathological alterations could
be based on an impairment in neurotrypsin/agrin system, as
supported by the literature (Zhang et al., 2013; Kim et al.,
2017) and our molecular observations: it is possible that MNs,
mainly affected by the lack of SMN, stop producing agrin
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(Zhang et al., 2013), but muscles can partially extend its
production.
Therapeutic Potential of Agrin Biological
NT-1654
Agrin biological NT-1654 consists in a 44 kDa fragment of the
C-terminal end of murine agrin: it is an engineered fragment,
neurotrypsin-resistant, highly soluble and retaining the AChR
clustering activity. Agrin NT-1654 can induce AChR clustering
when administered in vitro to C2C12 myotubes, and in vivo to
C57/Bl6 denervated mice (Hettwer et al., 2014).
In SMA mice, the synaptic pathology at the NMJ is
evident and appears at early symptomatic stage; sometimes also
morphologically intact NMJs can display functional alterations
(Murray et al., 2010). The lack of SMN protein impairs the post-
natal development of NMJs, affecting the maturation of AChR
clusters into pretzel-like profiles and leading to intermittent
neurotransmission failures (Kariya et al., 2008). Therefore, our
therapeutic approach starting at P0 aimed to prevent these events.
In agreement with the literature (Ling et al., 2010;
Dale et al., 2011), we observed that SMA NMJs display
remarkable abnormalities, such as immaturity, reduced size, NF
accumulation and denervation [present results, and (Valsecchi
et al., 2015)]. Similar defects have been also observed in
a sarcopenia murine model (neurotrypsin-overexpressing
SARCO mice), which is characterized by muscle loss similar
to the loss observed at late age: indeed these animals showed
NMJ fragmentation, defective innervation and incomplete
maturation. NT-1654 injections almost completely restored
the normal conditions, supporting the rebuilding of the
disassembled endplates (Hettwer et al., 2014). Here the treatment
with NT-1654 induced positive effects on NMJ morphology,
stimulating their maturation, probably by acting both on AChR
clustering and on agrin/Lrp4/MuSK signaling. Additionally, the
accumulation of NF, a typical SMA hallmark, was significantly
reduced after treatment. All these aspects can contribute to
reduce the impaired synaptic functions related to the disease (for
an extensive review see, Boido and Vercelli, 2016).
Due to the improved NMJ functionality/maturation, we also
observed a higher trophism of the muscles, probably due to
better innervation. Indeed, the mean fiber area was significantly
larger in NT-1654 SMA than in PBS controls, and also the
other analyzed parameters (muscle cross-sectional area andmean
number of muscle fibers) showed a similar positive trend.
Also the fiber composition was influenced by the treatment,
which restored the percentage of fiber type I (slow) and type II
(fast) close to WT values (Valsecchi et al., 2015). As described
by Dubowitz (1978), in case of SMA, type II fibers are the
most affected and are characterized by an extensive atrophy,
partially compensated by type I fibers. Other pathologies causing
muscle wasting (such as Duchennemuscular dystrophy or cancer
cachexia) show a similar fast-to-slow fiber type shift, with
type II fibers preferentially affected (Ciciliot et al., 2013). NT-
1654 administration was able to reverse the hybrid fibers (co-
expressing several myosin heavy chain isoforms) to the normal
segregation of type I and II fibers in SARCOmice, demonstrating
that such treatment can positively influence the muscle fiber
composition (Hettwer et al., 2014).
Additionally, the accumulation of NF, a typical SMA hallmark,
was significantly reduced after treatment. It has been suggested
that NF accumulation is due to a dysregulation of the axonal
transport machinery (Kreutzer et al., 2012) leading to an
impaired NMJ maturation and maintenance (Torres-Benito
et al., 2012). Even though the NF engulfment is still matter of
debate, our data support the hypothesis of a relationship between
NF accumulation, axonal transport and endplate development.
Overall, these observations demonstrate that NT-1654
administration improves innervation, supports NMJ maturation
and consequently influences the muscle trophism. However, the
positive effects observed at the peripheral level only partially
affect MN survival: a tendency in higher MN numbers was quite
evident in treated SMA mice vs. untreated ones, even though it
did not reach statistical significance.
Finally, the improvements observed at histological level were
also positively correlated with behavioral data. Indeed, we show
that NT-1654 administration results in a significant improvement
in SMA mice in the righting reflex, the tail suspension test and,
to a small extent, the hindlimb suspension test, indicating its
positive effect onweakness and fatigue. Additionally, survival was
slightly, but significantly, increased: we are aware that 1.5 days of
extended lifespan could appear poor, but it must be related to the
usually short SMA lifespan of around 14 days.
Other groups tried to rescue endplates and increase
muscle size in SMA, but the achieved improvements of
neuromuscular synaptic phenotypes often did not correlate
with similar positive outcomes concerning survival, motor
behavior or histological results (Paez-Colasante et al., 2013;
Wen et al., 2013). Indeed the agrin expression modulation
appears an effective target to positively influence the NMJ
establishment/maintenance, as recently demonstrated by Kim
et al. (2017): by generating SMN17 pups expressing a chicken
Z+Agrin cDNA driven by the motor neuron-specific Hb9
promoter (Hb9:Z+Agrin;SMN2;SMN∆7;Smn−/−), the authors
obtained results comparable to ours (i.e., muscular fiber and NMJ
size increase, NF reduction and improvedmuscular innervation).
Therefore, our pre-clinical work i) confirms the importance of
targeting agrin to delay the SMA progression, and ii) identifies an
effective compound (NT-1654) that could be potentially tested in
human trials.
Finally, we noticed that NT-1654 is able to induce some
positive effects also in WT mice, boosting the muscle size
(without significant effects on NMJmaturation and innervation).
These data suggest that NT-1654 can interfere with the muscular
homeostasis in healthy subjects, confirming that agrin can
also exert non-canonical functions, for example related to
skeletal muscle plasticity/differentiation (Gros et al., 2014) and
contractile apparatus maturation (Mis et al., 2013). Moreover,
the administration of NT-1654 in WT animals has demonstrated
that such treatment (i) does not negatively influence the correct
murine development, (ii) does not induce particular side effects
in pups and consequently (iii) can be considered safe. Moreover,
as shown in another study, NT-1654 does not induce immune
response, nor anti-agrin antibody production (Li et al., 2017).
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One of the major symptoms of SMA and other diseases
showing muscle atrophy consists in the loss of muscle strength,
which seriously impairs motor behavior of patients (Merlini
et al., 2004). Targeting agrin might represent a good strategy
to prevent muscle atrophy. Indeed, we can suppose that the
beneficial effects obtained by NT-1654 administration in our
SMAII experimental model could be greater in the milder forms
of SMA (e.g., SMAIII), where the pathological cascade affecting
MNs, NMJs andmuscles occurs more slowly, in this way allowing
a more extended therapeutic window.
Concluding Remarks on NT-1654
Mechanism of Action
As demonstrated by the above-mentioned histological and
behavioral observations, the administration of agrin biological
NT-1654 exerted beneficial effects in SMAmice. Actually, we can
only speculate about the mechanisms of action of such treatment,
and the relationship between SMN and agrin.
What is currently known is that SMA pups display a number
of neuropathological alterations ranging from delayed NMJ
maturation to NF accumulation at NMJs both in experimental
models (Ling et al., 2010) and in human patients (Martínez-
Hernández et al., 2013): a possible explanation for such
early abnormalities could be found in an impairment of
neurotrypsin/agrin system, as supported by a few evidence
in literature. In 2013, Zhang et al. (2013) demonstrated that
SMA MNs lack neuronal (Z+) agrin mRNA at P1, until its
complete disappearance at P3, in SMA17 mice. Based on
their observations, they suggest that SMA mice are capable of
expressing and producing Z+ agrin at P1: however, a problem
in the skipping of Z exons is responsible of the observed Z+
agrin protein deficiency, determining a consequent impairment
in postsynaptic AChR clustering. Here, by WB analysis, we
observed a significant decrease in the overall agrin expression
in the quadriceps of P10 SMA (as suggested by the reduced
expression of 110 kDa proteolytic fragment). It is plausible that
SMA17 mice suffer an initial decrease of Z+ agrin (Lefebvre
et al., 1997; Kim et al., 2017), followed by a general reduction of
the overall agrin.
Also referring to other pathologies (congenital myasthenia,
distal myopathy) the lack/mutation of agrin has been associated
to muscle weakness, atrophy and neurotransmission defects
(Nicole et al., 2014). Therefore, the administration of NT-1654
to our SMA experimental model has probably compensated
for the reduction of agrin. Similarly, transgenic expression of
a miniaturized form of agrin (“mini-agrin”), in combination
with anti-apoptosis treatment, provided benefit on the disease
progression in a mouse model of congenital muscular dystrophy,
stimulating stabilization ofmuscle fibers, muscle growth/strength
and regeneration (Meinen et al., 2011). Moreover, also
overexpressing Z+ agrin in MNs of Nova1/Nova2 double
knockout mice (an experimental model that show paralysis and
defective neuromuscular synapses) rescued AChR clustering,
but without restoring paralysis: the authors suggested that there
must be additional agrin-independent neuronal factors required
for MN function (Ruggiu et al., 2009).
Concerning SMA, other explanations for the treatment
success obtained with NT-1654 could be found in the
counteraction of the defects due to SMN lack. As known from the
literature, SMN deficiency affects the splicing machinery activity
(Lorson et al., 1999). Zhang demonstrated that SMN deficiency
causes transcriptome and proteome changes in MNs, affecting
specific genes necessary/detrimental for NMJ development,
including agrin (Zhang et al., 2013). Moreover, splicing defects
could also determine alterations in the microtubule-based motor
proteins (kinesin and dynein) and other interacting proteins,
justifying the well-known alteration of cellular trafficking
in SMA (Dale et al., 2011): notably, dynein can affect
the expression and the clustering of agrin-induced AChRs,
MuSK and Rapsyn; in addition defects in dynein can lead
to impairment of NMJs, and seem to be involved in ALS
neurodegeneration (Vilmont et al., 2016). Moreover, we cannot
exclude that also the transport of agrin could be affected/reduced.
Therefore, the NT-1654 administration could overcome such
deficiency.
Among the alterations described in SMA, it has been
also reported that SMN-deficient cells show a disorganized
actin cytoskeleton, affecting cell motility and myoblast
fusion/differentiation (Bricceno et al., 2014). Actin is also
necessary for AChR clustering and stabilization at the synapse:
agrin can trigger the association of a subset of membrane rafts
enriched in AChR and MuSK to the actin cytoskeleton (Cartaud
et al., 2011). Such defects in SMA could be partially restored by
NT-1654 administration, explaining the positive effects observed.
Moreover, many alterations in SMA type II seem to have an
embryonic onset: this should partially justify some limitations of
our therapy.
In conclusion, on the basis of our observations, agrin
biological NT-1654 represents a good therapeutic candidate
for SMA, counteracting agrin deficiency and SMN-induced
defects: it should be exploited in combination with the emerging
promising therapies aimed at increasing SMN expression.
Indeed, despite the first encouraging results coming from
gene therapy and ASO approaches, additional treatments are
needed to complement the benefits of CNS-directed and
SMN-dependent therapies (Bowerman et al., 2017), for the
following reasons: (i) the progressive deterioration of the
neuromuscular system may compromise the positive effects
due SMN-dependent treatments; (ii) many patients with milder
SMA forms do not meet the inclusion criteria requested
for clinical trials and may not benefit from SMN-inducing
treatments.
Moreover, potentially we expect similar results also for
other neuromuscular disorders affecting the motor system, such
as Charcot Marie Tooth syndrome, myasthenia gravis and
congenital myasthenic syndromes.
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